Table 1.
Characteristics of the Studies Included in the Analysis
| N | Study Title | Year | Method | Results |
|---|---|---|---|---|
| 1 | Epidermal growth factor therapy and wound healing—past, present, and future perspectives30 | 2008 | Review in Medline | The FCE showed positive results in the wound healing process, but due to its topical application it has been criticized due to the limited effect on the healing of chronic wounds and the association with invasive malignancies at local level |
| 2 | An approach to treating ulcers of vascular origin: review and role of epidermal growth factor26 | 2016 | Evidence Review | The review of scientific evidence of (rhEGF) for vascular ulcers shows that it has efficacy, and tolerability, considered as an adjunctive or emerging treatment that can be considered for the management of vascular ulcers. |
| 3 | Comparative study of Four Layer Compression Bandaging and Topical Human Epidermal Growth Factor in Chronic Venous Leg Ulcer31 | 2018 | A prospective, open-label, randomized, comparative, single-center study | Topical h-EGF along with the four-layer bandage speeds the healing time in chronic leg venous ulcer |
| 4 | Human recombinant epidermal growth factor in skin lesions: 77 cases in EPithelized project32 | 2018 | Multicenter case series | Topical rhEGF presents results in effectiveness and tolerance. It is not compared with other technologies or drug presentations. |
| 5 | A new alternative in the management of complex vascular ulcer with recombinant epidermic growth factor, EPIPROT® (Nepidermine)33 | 2019 | Follow-up to three cases | rhEGF contributes to granulation and stimulates short term healing, which can reduce complications. |
| 6 | Treatment of venous ulcers with growth factors: systematic review and meta-analysis34 | 2019 | Systematic Review | The effect of the application of growth factors for complete healing in venous ulcers is not clear, clinical trials with methodological quality are necessary for more precise recommendations. |
| 7 | Experience with the use of perilesional and intralesional recombinant human epidermal growth factor (nepidermin) in the treatment of patients with chronic venous ulcers25 | 2019 | Retrospective multicenter case series study | rhEGF achieved an important level of improvement in the severity index of the injury, which allowed epithelialization and wound healing in most cases in a brief period of time |
| 8 | Clinical guideline on topical growth factors for skin wounds35 | 2020 | GPC for the application of growth factors | Topical application of growth factors is promising in the treatment of several types of skin wounds |
| 9 | Efficacy of Human Recombinant Epidermal Growth Factors vs Conventional Therapy for the Treatment of Chronic Venous Ulcers: A Retrospective Case Series36 | 2021 | Case Series Retrospective Study | rhEGF presents a higher probability of epithelization of venous ulcers compared to hydrocolloids |
| 10 | Growth factors for treating chronic venous leg ulcers: A systematic review and meta-analysis15 | 2022 | Systematic Review | EGFs can increase the percentage of reduced ulcer area during treatment |